JP2024524222A5 - - Google Patents
Info
- Publication number
- JP2024524222A5 JP2024524222A5 JP2023578940A JP2023578940A JP2024524222A5 JP 2024524222 A5 JP2024524222 A5 JP 2024524222A5 JP 2023578940 A JP2023578940 A JP 2023578940A JP 2023578940 A JP2023578940 A JP 2023578940A JP 2024524222 A5 JP2024524222 A5 JP 2024524222A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- nucleoside
- complex according
- seq
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163212816P | 2021-06-21 | 2021-06-21 | |
| US63/212,816 | 2021-06-21 | ||
| PCT/US2022/033956 WO2022271543A2 (en) | 2021-06-21 | 2022-06-17 | Muscle targeting complexes and uses thereof for treating friedreich's ataxia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524222A JP2024524222A (ja) | 2024-07-05 |
| JP2024524222A5 true JP2024524222A5 (https=) | 2025-06-25 |
Family
ID=84545809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578940A Pending JP2024524222A (ja) | 2021-06-21 | 2022-06-17 | 筋標的化複合体およびフリードライヒ運動失調症を処置するためのその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250099603A9 (https=) |
| EP (1) | EP4359008A4 (https=) |
| JP (1) | JP2024524222A (https=) |
| CN (1) | CN118251238A (https=) |
| CA (1) | CA3222816A1 (https=) |
| WO (1) | WO2022271543A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10517877B2 (en) * | 2016-03-30 | 2019-12-31 | Wisconsin Alumni Research Foundation | Compounds and methods for modulating frataxin expression |
| US11459564B2 (en) * | 2017-12-21 | 2022-10-04 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
| KR20210086601A (ko) * | 2018-08-02 | 2021-07-08 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도 |
-
2022
- 2022-06-17 CN CN202280050965.4A patent/CN118251238A/zh active Pending
- 2022-06-17 JP JP2023578940A patent/JP2024524222A/ja active Pending
- 2022-06-17 WO PCT/US2022/033956 patent/WO2022271543A2/en not_active Ceased
- 2022-06-17 CA CA3222816A patent/CA3222816A1/en active Pending
- 2022-06-17 US US18/572,321 patent/US20250099603A9/en active Pending
- 2022-06-17 EP EP22829057.3A patent/EP4359008A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024524222A5 (https=) | ||
| JP2023535078A5 (https=) | ||
| JP2024503609A5 (https=) | ||
| JP2023509793A5 (https=) | ||
| JP2023512441A5 (https=) | ||
| IL309910A (en) | Muscle targeting complexes and their uses for the treatment of myotonic dystrophy | |
| JP2023510350A5 (https=) | ||
| JP7447073B2 (ja) | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド | |
| JP2024160045A5 (https=) | ||
| JP2024527362A5 (https=) | ||
| JP2023535073A5 (https=) | ||
| JP2024546436A5 (https=) | ||
| JP2024501872A5 (https=) | ||
| JP2024525611A5 (https=) | ||
| IL309936A (en) | Muscle targeting complexes and formulations for the treatment of dystrophinopathy | |
| JP2024525610A5 (https=) | ||
| JP2023510351A5 (https=) | ||
| JP2021533197A5 (https=) | ||
| JP2021533199A5 (https=) | ||
| JP2023512442A5 (https=) | ||
| JP2024525613A5 (https=) | ||
| JP2025512469A5 (https=) | ||
| JP2024525614A5 (https=) | ||
| JP2024525612A5 (https=) | ||
| IL316143A (en) | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |